Fildena and vardenafil were also shown to enhance tumour permeability via effects on the blood brain barrier 26 Specifically looking to address the blood-brain tumour barrier, which includes the microvessel supplying brain tumours, Black et al. showed that oral Fildena (50 mg/kg) and vardenafil (10 mg/kg) increased tumour permeability of radioactively labelled sucrose. Multidrug resistance protein 5 (MRP5/ABCC5) was shown to confer resistance to the commonly used cancer drug 5-FU in human embryonic kidney cells in vitro, increasing the EC50 value by a factor of ten in cells transfected with MRP5 compared to non-transfected cells 79 It was further shown that a number of agents, including Fildena, could reduce the ATP-dependent transport of active 5-FU metabolites. In vivo combination treatment with pemetrexed and Fildena enhanced the anti-tumour efficacy of checkpoint inhibitory antibodies directed against programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA4).

They showed that MDSC reduced both T cell proliferation and ζ-chain T cell receptor expression, thereby creating an immunosuppressive tumour microenvironment 77 Treatment with Fildena reduced MDSC numbers infiltrating primary tumours and metastatic lesions, increased CD8 T cells and induced a partial recovery of ζ-chain expression. Serafini et al. 19 first outlined the immunomodulatory effects of PDE5 inhibitors in relation to cancer in 2006. The role of PDE5 in different tissues and diseases is reviewed by Kouvelas et al. 76 , here we will focus on the different mechanisms of action which have been explored in relation to the anti-cancer effects of the PDE5 inhibitors discussed in this review.

As of 24 August 2017, a number of clinical trials are investigating the anti-cancer uses of Fildena, Fildena and vardenafil, as shown in Table 4 Note that trials which are assessing non-cancer-related outcomes, for example trials such as NCT01375699 which is assessing the cardio-protective effect of Fildena on doxorubicin-treated cancer patients are not included. Concerns were also raised that long-term PDE5 inhibitor use might increase the risk of biochemical relapse after radical prostatectomy for localised prostate cancer 73 Michl et al. reported that use of a PDE5 inhibitor after radical prostatectomy was associated with an increased risk of biochemical recurrence (HR 1.38, 95% CI 1.11-1.70, P = 0.0035). A meta-analysis by Tang et al. 71 concluded that PDE5 inhibitor use was associated with a slightly elevated risk of melanoma (OR, 1.12; 95% CI 1.03-1.21) and basal cell carcinoma (OR, 1.14; 95% CI 1.09-1.19) but not squamous cell carcinoma, however they concluded that causality remained elusive.

Stable disease was achieved in 3/12 patients (25%), with median progression-free survival (PFS) of 4.6 months (range 0.7-7.1) and overall survival (OS) 8.5 months (range 2.7-23.7). Patients with stable disease displayed significantly higher pre-treatment CD8 TILs in the centre of metastases and after therapy showed increased expression of ζ-chain in CD8 and CD4 TILs and CD8 T cells in the peripheral blood. The authors hypothesised that the increased blood flow due to Fildena when used for erectile dysfunction would be beneficial in reducing hypoxia and hence improving response to radiotherapy.
https://www.wingate.edu/majors-programs/school-of-pharmacy/
https://victor-perrin.fr/
http://www.lsbme.la.gov/
http://www.news-medical.net/health/What-is-Impotence-(Erectile-Dysfunction).aspx
https://www.medicinenet.com/script/main/art.asp?articlekey=17038